Recent study reported that sarcoma patients with more SPP1hi TAMs had poorer clinical outcomes, whereas patients with more CXCL9hi TAMs had better ones.[18] And we found that OCDM treatment inhibited the CXCL9:SPP1 polarity of BMDMs. Here, CXCL9 is linked to sarcoma.